Adoptive immunotherapy of cancer

J. S. Weber, S. A. Rosenberg

Research output: Contribution to journalReview articlepeer-review

Abstract

Adoptive cellular immunotherapy uses immune cells isolated from tumor bearing patients that are grown ex vivo in the presence of interleukin-2 and administered to patients along with high doses of interleukin-2. Data from animal models suggested that lymphokine activated killer (LAK) cells have therapeutic efficacy when administered with interleukin-2. LAK cells, which are non-major histocompatibility complex restricted anti-tumor effectors, cause objective responses in a significant percentage of patients with melanoma, renal cell carcinoma, non-Hodgkin's lymphoma, and colorectal cancer. Tumor infiltrating lymphocytes are classic cytolytic T cells isolated from murine and human tumors. They are more therapeutically effective in experimental murine tumor models and have been shown to cause objective responses in 50% of a small series of patients with advanced melanoma who simultaneously receive high dose interleukin-2.

Original languageEnglish (US)
Pages (from-to)381-400
Number of pages20
JournalImmunology and Allergy Clinics of North America
Volume11
Issue number2
StatePublished - Jan 1 1991

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint

Dive into the research topics of 'Adoptive immunotherapy of cancer'. Together they form a unique fingerprint.

Cite this